You are now leaving the pages of www.gilead.com intended for U.S. audiences. The information in this section is intended for visitors outside the United States.
Isis Acquires Antisense Patent and Technology Estate from Gilead Sciences
Gilead Announces Third Quarter 1998 Financial Results
Gilead announces that partner Hoffmann-La Roche discloses GS 4104 Phase III study results
Gilead Sciences Provides Update on PREVEON® Clinical Program for the Treatment of HIV
Gilead Sciences Begins Phase II Human Testing of Oral PMPA for Treatment of HIV; Combinations Including Hydroxyurea to be Evaluated
Gilead Announces Second Quarter 1998 Financial Results
Gilead Announces Preliminary Results From Phase II/III Studies for New Product to Treat or Prevent Influenza
Gilead Sciences Announces Termination of Genetic Code Blocker Research Collaboration with Glaxo Wellcome
12th World Aids Conference To Be Broadcast On World Wide Web
Dr. Paul Berg Joins Gilead Sciences Board of Directors
Gilead Announces First Quarter 1998 Financial Results
Gilead Announces Adefovir Dipivoxil Reduces Hepatitis B Levels by More than 99 Percent in Chronically Infected Patients
Gilead Broadens HIV Expanded Access Program for PREVEON®
Cidofovir Reported to Have Activity Against Poxvirus Infection in Primates
Flu Patients in United States May Now Have Access to Experimental Oral Treatment for Influenza
Gilead Announces Fourth Quarter and 1997 Year-end Financial Results
Gilead Announces Presentation of Phase I/II Study Results of Oral PMPA for HIV at Upcoming Medical Conference
2012 Interactive Annual Report